دورية أكاديمية
أعرض في EDS

Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.

التفاصيل البيبلوغرافية
العنوان: Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
المؤلفون: Rekhtman N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. rekhtman@mskcc.org., Desmeules P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pathology, Quebec Heart and Lung Institute, Quebec, QC, Canada., Litvak AM; Thoracic Oncology Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Cancer Center at Saint Barnabas Medical Center, Livingston, NJ, USA., Pietanza MC; Thoracic Oncology Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Merck Research Laboratories, Rahway, NJ, USA., Santos-Zabala ML; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ni A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Montecalvo J; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chang JC; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Beras A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Preeshagul IR; Thoracic Oncology Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sabari JK; Thoracic Oncology Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; New York University Langone's Perlmutter Cancer Center, New York, NY, USA., Rudin CM; Thoracic Oncology Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Klimstra DS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Travis WD; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lai WC; Thoracic Oncology Service, Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
المصدر: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2019 Jul; Vol. 32 (8), pp. 1106-1122. Date of Electronic Publication: 2019 Mar 28.
نوع المنشور: Comparative Study; Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 8806605 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-0285 (Electronic) Linking ISSN: 08933952 NLM ISO Abbreviation: Mod Pathol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2023- : [New York] : Elsevier Inc.
Original Publication: Baltimore, MD : Williams & Wilkins, c1988-
مواضيع طبية MeSH: Cell Proliferation* , Mitosis*, Carcinoid Tumor/*secondary , Lung Neoplasms/*pathology , Neuroendocrine Tumors/*secondary, Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Carcinoid Tumor/chemistry ; Carcinoid Tumor/genetics ; Diagnosis, Differential ; Disease Progression ; Female ; Humans ; Ki-67 Antigen/analysis ; Lung Neoplasms/chemistry ; Lung Neoplasms/genetics ; Male ; Middle Aged ; Mitotic Index ; Neoplasm Staging ; Neuroendocrine Tumors/chemistry ; Neuroendocrine Tumors/genetics ; Predictive Value of Tests
مستخلص: The spectrum and evolution of proliferation rates in stage IV lung carcinoids is poorly defined. In particular, there are limited data on the prevalence and characteristics of tumors exceeding the standard upper proliferative criteria-as defined largely based on early-stage carcinoids-in metastatic setting. Sixty-six patients with stage IV lung carcinoids were identified, and all evaluable samples (n = 132; mean 2 samples per patient) were analyzed for mitotic counts and Ki-67 rate. Clinicopathologic and genomic features associated with elevated proliferation rates (>10 mitoses per 2 mm 2 and/or >20% hot-spot Ki-67), and evolution of proliferation rates in serial specimens were analyzed. We found that mitoses and/or Ki-67 exceeded the standard criteria in 35 of 132 (27%) samples, primarily (31/35 cases) at  metastatic sites. Although neuroendocrine neoplasms with >10 mitoses per 2 mm 2 are currently regarded as de facto neuroendocrine carcinomas, the notion that these cases are part of the spectrum of carcinoids was supported by (1) well-differentiated morphology, (2) conventional proliferation rates in other samples from same patient, (3) genetic characteristics, including the lack of RB1/TP53 alterations in all tested samples (n = 19), and (4) median overall survival of 2.7 years, compared to <1 year survival of stage IV neuroendocrine carcinomas in the historic cohorts. In patients with matched primary/metastatic specimens (48 pairs), escalation of mitoses or Ki-67 by ≥10 points was observed in 35% of metastatic samples; clonal relationship in one pair with marked proliferative progression was confirmed by next-generation sequencing. Notably, escalation of proliferation rate was documented in a subset of metastases arising from resected typical carcinoids, emphasizing that the diagnosis of typical carcinoid in primary tumor does not assure low proliferation rate at metastatic sites. In conclusion, stage IV lung carcinoids frequently exceed the standard proliferative criteria established for primary tumors, and commonly exhibit proliferative escalation at metastatic sites. Despite the overlap of proliferation rates, these tumors show fundamental morphologic, genomic and clinical differences from neuroendocrine carcinomas, and should be classified separately from those tumors. Awareness of the increased proliferative spectrum in metastatic carcinoids is critical for their accurate diagnosis. Further studies are warranted to explore the impact of proliferation indices on prognosis and therapeutic responses of patients with metastatic carcinoids.
References: Nat Commun. 2014 Mar 27;5:3518. (PMID: 24670920)
Am J Surg Pathol. 2005 Feb;29(2):179-87. (PMID: 15644774)
Hematol Oncol Clin North Am. 2016 Feb;30(1):1-19. (PMID: 26614366)
J Thorac Dis. 2017 Nov;9(Suppl 15):S1435-S1441. (PMID: 29201446)
J Natl Compr Canc Netw. 2018 Jun;16(6):693-702. (PMID: 29891520)
Chest. 2017 May;151(5):1141-1146. (PMID: 27373769)
Am J Clin Pathol. 2015 Mar;143(3):398-404. (PMID: 25696798)
Pancreas. 2017 Mar;46(3):296-301. (PMID: 27759713)
Am J Surg Pathol. 2015 May;39(5):683-90. (PMID: 25723112)
Endocr Relat Cancer. 2013 Aug 19;20(5):649-57. (PMID: 23845449)
Am J Clin Pathol. 2000 Mar;113(3):345-50. (PMID: 10705813)
Ann Thorac Surg. 2013 Oct;96(4):1156-1162. (PMID: 23915584)
Hum Pathol. 2000 Oct;31(10):1255-65. (PMID: 11070119)
Arch Pathol Lab Med. 2018 Aug;142(8):947-951. (PMID: 29869902)
Arch Pathol Lab Med. 2010 Nov;134(11):1628-38. (PMID: 21043816)
Am J Clin Pathol. 2003 Aug;120(2):209-16. (PMID: 12931551)
Pathol Oncol Res. 2003;9(3):198-200. (PMID: 14530817)
J Thorac Oncol. 2016 Mar;11(3):300-11. (PMID: 26723244)
Ann Oncol. 2015 Aug;26(8):1604-20. (PMID: 25646366)
Neuroendocrinology. 2017;104(1):85-93. (PMID: 26943788)
Virchows Arch. 2017 Jul;471(1):31-47. (PMID: 28451756)
Cancer. 1982 Apr 15;49(8):1652-7. (PMID: 6279270)
Eur J Surg Oncol. 2014 Nov;40(11):1517-22. (PMID: 25088936)
Mod Pathol. 2018 Dec;31(12):1770-1786. (PMID: 30140036)
Int J Cancer. 2016 Dec 15;139(12):2679-2686. (PMID: 27553864)
Mod Pathol. 2018 Oct;31(10):1523-1531. (PMID: 29802361)
Clin Transl Oncol. 2018 May;20(5):670-677. (PMID: 29022170)
J Thorac Oncol. 2016 Mar;11(3):e35-8. (PMID: 26723240)
Am J Surg Pathol. 2016 Sep;40(9):1192-202. (PMID: 27259015)
Clin Cancer Res. 2016 Feb 15;22(4):1011-7. (PMID: 26482044)
Neuroendocrinology. 2016;103(2):172-85. (PMID: 26731013)
Am J Surg Pathol. 2010 Mar;34(3):300-13. (PMID: 20118772)
Virchows Arch. 2017 Feb;470(2):153-164. (PMID: 28054150)
J Thorac Oncol. 2014 Mar;9(3):273-84. (PMID: 24518085)
Cancer. 2004 Dec 1;101(11):2605-13. (PMID: 15495181)
J Clin Pathol. 2002 Apr;55(4):293-7. (PMID: 11919216)
Clin Cancer Res. 2016 Jul 15;22(14):3618-29. (PMID: 26960398)
Neuroendocrinology. 2016;103(5):452-9. (PMID: 26337010)
Am J Surg Pathol. 2011 Jun;35(6):853-60. (PMID: 21566513)
J Clin Oncol. 2006 Oct 1;24(28):4539-44. (PMID: 17008692)
Lancet Oncol. 2014 Jan;15(1):e8-21. (PMID: 24384494)
Clin Cancer Res. 2017 Aug 15;23(16):4625-4632. (PMID: 28455360)
Lung Cancer. 2011 Jan;71(1):34-41. (PMID: 20462655)
Am J Surg Pathol. 1998 Aug;22(8):934-44. (PMID: 9706973)
PLoS One. 2017 Jun 23;12(6):e0179445. (PMID: 28644861)
Nature. 2015 Aug 6;524(7563):47-53. (PMID: 26168399)
Nat Commun. 2018 Mar 13;9(1):1048. (PMID: 29535388)
Clin Lung Cancer. 2016 Sep;17(5):e121-e129. (PMID: 26898325)
Clin Cancer Res. 2008 Apr 1;14(7):1938-46. (PMID: 18381931)
Am J Surg Pathol. 2012 Feb;36(2):173-84. (PMID: 22251937)
Virchows Arch. 2017 Dec;471(6):713-720. (PMID: 28631159)
Am J Surg Pathol. 2017 Feb;41(2):263-270. (PMID: 27879513)
Endocr Relat Cancer. 2015 Aug;22(4):657-64. (PMID: 26113608)
Endocr Relat Cancer. 2013 Dec 16;21(1):1-16. (PMID: 24344249)
J Mol Diagn. 2015 May;17(3):251-64. (PMID: 25801821)
Lung Cancer. 2014 Nov;86(2):241-6. (PMID: 25218177)
معلومات مُعتمدة: P30 CA008748 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (Ki-67 Antigen)
0 (MKI67 protein, human)
تواريخ الأحداث: Date Created: 20190330 Date Completed: 20200427 Latest Revision: 20240720
رمز التحديث: 20240720
مُعرف محوري في PubMed: PMC6746332
DOI: 10.1038/s41379-019-0248-2
PMID: 30923345
قاعدة البيانات: MEDLINE
الوصف
تدمد:1530-0285
DOI:10.1038/s41379-019-0248-2